Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung

被引：0
作者：
Naoko Imanishi
Kazue Yoneda
Akihiro Taira
Yoshinobu Ichiki
Naoko Sato
Masanori Hisaoka
Fumihiro Tanaka
机构：
[1] University of Occupational and Environmental Health Japan,Second Department of Surgery (Chest Surgery)
[2] University of Occupational and Environmental Health Japan,Department of Pathology, School of Medicine
[3] University of Occupational and Environmental Health Japan,Department of Pathology and Oncology, School of Medicine
来源：
Surgical Case Reports | / 4卷 / 1期
关键词：
ALK; Alectinib; Pathologic response; Adenocarcinoma; Lung;
D O I：
10.1186/s40792-018-0430-7
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 28 条
[1]  
Solomon BJ(2014)First-line crizotinib versus chemotherapy in ALK-positive lung cancer N Engl J Med 371 2167-2177
[2]  
Mok T(2017)Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial Lancet 390 29-39
[3]  
Kim DW(2017)Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer N Engl J Med 377 829-838
[4]  
Wu YL(2015)Surgical resection of lung adenocarcinoma after crizotinib treatment: report of a case World J Surg Oncol 13 74-893
[5]  
Nakagawa K(2017)Off-label use of crizotinib as a neoadjuvant treatment for a young patient when conventional chemotherapy gave no benefits in stage IIIA non-small cell lung cancer Am J Case Rep 18 890-undefined
[6]  
Mekhail T(undefined)undefined undefined undefined undefined-undefined
[7]  
Hida T(undefined)undefined undefined undefined undefined-undefined
[8]  
Nokihara H(undefined)undefined undefined undefined undefined-undefined
[9]  
Kondo M(undefined)undefined undefined undefined undefined-undefined
[10]  
Kim YH(undefined)undefined undefined undefined undefined-undefined
123